Publication & Citation Trends
Publications
0 total
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Cited by 333
Semantic Scholar
Expeditious synthesis of C2- or N4-aryl-1,4-benzothiazin-3-one via orthogonal Pd-catalyzed C-arylation and Cu-catalyzed N-arylation
Cited by 5
Semantic Scholar
Expeditious Synthesis of C2‐ or N4‐Aryl‐1,4‐benzothiazin‐3‐one via Orthogonal Pd‐Catalyzed C‐Arylation and Cu‐Catalyzed N‐Arylation.
Cited by 0
Semantic Scholar
Facile Synthesis of 1,4‐Benzothiazin‐3‐ones from Cu‐Catalyzed Coupling of 2‐Iodoanilines and 2‐Mercaptoacetate.
Cited by 14
Semantic Scholar
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.
Cited by 86
Semantic Scholar
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
Cited by 179
Semantic Scholar
Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)
Cited by 12
Semantic Scholar
Studies on quinazolinones as dual inhibitors of Pgp and MRP1 in multidrug resistance.
Cited by 33
Semantic Scholar
Research Topics
Cancer therapeutics and mechanisms
(2)
Synthesis and biological activity
(1)
Drug Transport and Resistance Mechanisms
(1)
Virus-based gene therapy research
(1)
RNA Interference and Gene Delivery
(1)
Affiliations
University of Auckland
Cancer Society of New Zealand